Saturday 17 October 2026
Export OWLT’s income statement to Excel — free account
Owlet, Inc.
OWLT Healthcare Medical Devices
In the quarter to June 2026, revenue grew 29.9%, EPS grew 97.9%, free cash flow grew 55.7% and total debt fell 16.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
4.14
0.30
−6.76%
Follow OWLT
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '17 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 5 | 6 | 1 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
2.77 | 0.62 | 0.88 | 0.92 | 2.22 | 0.00 | — |
Altman Z-Score |
(0.37) | (6.71) | (8.81) | (8.76) | (0.44) | 0.71 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(8.89) | (19.43) | (24.44) | (24.18) | (2.21) | (8.94) | — |
P/Operating CF |
(648.10) | 16.21 | (30.19) | (6.46) | (28.83) | (30,685.34) | — |
Beneish M-Score |
(3.37) | (2.68) | (3.64) | (0.07) | (3.57) | — | — |
P/B ratio |
15.38 | 0.00 | 0.00 | 0.00 | 3.06 | 20.50 | — |
Price to Tangible BV |
16.60 | 0.00 | 0.00 | 0.00 | 3.15 | 20.56 | — |
EV/Sales |
2.51 | 0.51 | 0.87 | 1.00 | 1.19 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(24.55) | (3.55) | (1.99) | (0.85) | (2.22) | 0.00 | — |
EV/FCF |
(22.58) | (3.32) | (1.98) | (0.84) | (2.12) | 0.00 | — |
Quick Ratio |
1.45 | 0.90 | 0.68 | 0.41 | 1.53 | 0.58 | — |
Current Ratio |
1.85 | 1.27 | 0.89 | 0.77 | 1.97 | 0.80 | — |
Net Debt/EBITDA |
5.12 | 0.56 | 0.05 | (0.05) | 1.44 | (0.80) | — |
Debt/Assets |
15.22% | 23.62% | 34.44% | 25.88% | 11.80% | 54.60% | 0.00% |
Debt/Equity |
0.42 | (0.55) | (0.51) | (1.41) | 0.30 | (1.05) | — |
Asset Turnover |
1.56 | 1.67 | 1.06 | 0.70 | 0.84 | 3.76 | — |
Operating CF/Net income |
0.26 | 0.65 | 0.63 | 1.03 | 0.57 | 0.01 | — |
Capex/Depreciation |
(0.34) | (0.17) | (0.03) | (0.59) | (1.78) | (1.21) | — |
Interest Coverage |
(2.42) | (12.40) | (8.97) | (76.65) | (2.00) | (5.06) | — |
| 781.68% | 51.18% | 155.68% | (356.12%) | 1,118.80% | (8.25%) | — | |
| (61.94%) | (36.77%) | (73.35%) | (80.08%) | (79.60%) | (52.45%) | — | |
ROIC |
(168.95%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Return on Tangible Assets |
(110.23%) | (175.94%) | 786.16% | 557.45% | (104.53%) | 132.51% | — |
Average Days of Receivables |
79.18 | 56.75 | 94.43 | 84.17 | 50.38 | 50.95 | — |
Research and Development Expense of Revenue |
13.32% | 12.56% | 19.16% | 40.31% | 28.25% | 13.88% | — |
Selling, General and Administrative Expense of Revenue |
45.14% | 63.71% | 75.67% | 115.66% | 91.54% | 42.97% | — |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.05 | 0.04 | 0.01 | 0.02 | 0.00 |
Share Based Compensation of Revenue |
8.84% | 11.06% | 18.39% | 18.58% | 5.62% | 1.42% | — |
Graham Net Nets |
0.09 | (0.50) | (0.71) | (0.28) | 0.30 | (0.01) | — |
Graham Number |
0.00 | 9.22 | 21.52 | 17.30 | 0.00 | 0.00 | — |
Earnings Yield |
(15.32%) | (31.24%) | (78.97%) | (124.61%) | (43.84%) | (0.10%) | — |
Free Cash Flow Yield |
(4.01%) | (24.57%) | (49.56%) | (130.73%) | (25.23%) | 0.00% | — |
Revenue per Share |
5.84 | 7.13 | 6.53 | 8.70 | 16.80 | 48.10 | — |
Operating CF per Share |
(0.60) | (1.02) | (2.84) | (10.24) | (8.99) | (0.08) | — |
Capex per Share |
(0.05) | (0.07) | (0.01) | (0.20) | (0.45) | (0.67) | — |
Free Cash Flow per Share |
(0.65) | (1.09) | (2.85) | (10.43) | (9.43) | (0.76) | — |
Cash per Share |
2.27 | 1.88 | 2.00 | 1.41 | 21.06 | 10.85 | — |
Shareholders Equity per Share |
1.72 | (1.93) | (3.59) | (1.34) | 12.23 | (13.28) | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
1.72 | (1.93) | (3.59) | (1.34) | 12.23 | (13.28) | — |
Free Cash Flow |
(11.73) | (11.97) | (23.59) | (82.94) | (42.58) | (1.18) | — |
Working Capital |
37.67 | 9.68 | (5.15) | (15.34) | 66.73 | (9.66) | — |
Capital Expenditures |
(0.94) | (0.76) | (0.06) | (1.56) | (2.02) | (1.06) | — |
Net Current Asset Value |
27.32 | (24.55) | (33.85) | (17.48) | 50.96 | (23.32) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.01 | 0.01 | 0.00 | 0.02 | 0.03 | 0.01 | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||||
Depreciation/Fixed assets |
9.46 | 42.94 | 5.94 | 2.41 | 0.61 | 0.51 | — |
Cash ROIC |
(13.79%) | (107.07%) | (1,136.67%) | (530.54%) | (25.53%) | (6.55%) | — |
Accounts Receivable Turnover |
6.03 | 5.98 | 3.61 | 5.24 | 7.23 | 7.18 | — |
Accounts Payable Turnover |
4.49 | 3.10 | 1.42 | 1.58 | 1.85 | 1.79 | — |
Inventory Turnover |
4.04 | 4.55 | 2.51 | 2.51 | 3.15 | 3.05 | — |
Average Days of Payables |
83.72 | 106.27 | 158.89 | 242.06 | 248.49 | 151.25 | — |
Days of Inventory on Hand |
106.97 | 99.13 | 75.42 | 147.27 | 160.91 | 73.06 | — |
Average Receivables |
17.53 | 13.05 | 14.97 | 13.21 | 10.50 | 10.50 | — |
Average Payables |
11.62 | 12.48 | 22.06 | 29.10 | 22.07 | 22.07 | — |
Average Inventory |
12.91 | 8.51 | 12.50 | 18.25 | 12.95 | 12.95 | — |
Average Assets |
67.57 | 46.82 | 51.11 | 99.08 | 90.08 | 20.06 | — |
Average Common Equity |
(5.35) | (33.64) | (24.08) | 22.28 | (6.41) | 127.46 | — |
Columns are period end dates